2024-03-29T07:20:38Z
https://zenodo.org/oai2d
oai:zenodo.org:4616313
2021-12-30T14:27:30Z
user-covid-nma
Lina Ghosn
Anna Chaimani
Theodoros Evrenoglou
Mauricia Davidson
Carolina Graña
Christine Schmucker
Claudia Bollig
Nicholas Henschke
Yanina Sguassero
Camila Hansen Nejstgaard
Sonia Menon
Thu Van Nguyen
Gabriel Ferrand
Philipp Kapp
Carolina Riveros
Camila Ávila
Declan Devane
Joerg J Meerpohl
Gabriel Rada
Asbjørn Hróbjartsson
Giacomo Grasselli
David Tovey
Philippe Ravaud
Isabelle Boutron
2021-03-18
<p>Table of outcomes effect size and relevant forest plots per outcome for IL-6 blocking agents (Tocilizumab/sarilumab) as compared to standard of care/placebo; including primary analysis, sensitivity and subgroup analysis.</p>
https://doi.org/10.5281/zenodo.4616313
oai:zenodo.org:4616313
eng
Zenodo
https://doi.org/10.1002/14651858.CD013881
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.4605398
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Interleukin-6 blocking agents for treating COVID-19:Table of outcomes effect size and forest plots per outcome
info:eu-repo/semantics/other
oai:zenodo.org:3959133
2020-08-13T15:23:04Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-23
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of protocols for RCTs on preventive measures and treatments for Covid-19.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3959133
oai:zenodo.org:3959133
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3931394
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Protocols for RCTs on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3983031
2020-08-14T00:59:23Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-13
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of protocols for RCTs on preventive measures and treatments for Covid-19.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3983031
oai:zenodo.org:3983031
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3931394
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Protocols for RCTs on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3820266
2023-10-09T09:29:54Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-11
<p>WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.</p>
<p>To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).</p>
<p>This protocol details the process and methods we will use.</p>
https://doi.org/10.5281/zenodo.3820266
oai:zenodo.org:3820266
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3744599
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review
info:eu-repo/semantics/report
oai:zenodo.org:3931413
2020-08-07T14:27:33Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-06
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3931413
oai:zenodo.org:3931413
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3968308
2020-08-07T14:27:34Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-31
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3968308
oai:zenodo.org:3968308
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3835799
2020-08-07T14:27:32Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-20
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3835799
oai:zenodo.org:3835799
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3975817
2020-08-09T00:59:24Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-07
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3975817
oai:zenodo.org:3975817
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3975662
2020-08-13T15:11:27Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-07
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3975662
oai:zenodo.org:3975662
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3855119
2020-08-13T15:11:23Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-26
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3855119
oai:zenodo.org:3855119
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3968309
2020-08-13T15:11:26Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-31
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3968309
oai:zenodo.org:3968309
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3983011
2020-08-14T00:59:23Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-13
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3983011
oai:zenodo.org:3983011
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3878755
2020-08-13T15:11:24Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-05
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3878755
oai:zenodo.org:3878755
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:5810076
2022-09-28T07:46:09Z
user-covid-nma
user-covid-19
Phillip Kapp
Isabelle Boutron
2021-12-30
<p>We aimed to assess transparency of reporting and risk of bias of randomized trials evaluating interventions aimed at preventing and treating COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly.</p>
https://doi.org/10.5281/zenodo.5810076
oai:zenodo.org:5810076
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5810075
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
COVID-19, reporting,CONSORT, transparency of reporting, randomized trials, RCT
Monitoring feedback to authors on the quality of trials evaluating interventions aimed at preventing and treating COVID-19
info:eu-repo/semantics/article
oai:zenodo.org:4266529
2020-11-12T12:27:11Z
user-covid-nma
openaire_data
user-covid-19
Thu Van Nguyen
Gabriel Ferrand
Sarah Cohen-Boulakia
Ruben Martinez
Philipp Kapp
Emmanuel Coquery
Julia Baudry
Françoise Conil
Ameer Hohlfeld
Bastien Doreau
Gilles Feron
Farouk Toumani
Marinette Bouet
Mohand-Saïd Hacid
Mathilde Fouet
Joly Ghanawi
Dachi Arikpo
Solaf Alawadhi
Emina Zoletic
Philippe Ravaud
Isabelle Boutron
for the COVID-NMA consortium
2020-04-01
<p>Every week we screen the WHO International Clinical Trials Registry Platform (ICTRP) to identify and extract data from RCTs evaluating the effectiveness of interventions for preventing and treating COVID-19 as well as of all trials assessing vaccines.</p>
<p>This dataset includes a detailed list of all the RCTs we have identified, including their characteristics (i.e. registration date, study design, study aim, funding, country, etc.). This data is being used to develop our two living data visualizations of <a href="https://covid-nma.com/dataviz/">treatments</a> and <a href="https://covid-nma.com/vaccines/mapping/">vaccines</a>.</p>
<p>This is the first version of the database, dated 1st April 2020. Since then, the file has been updated once a week. </p>
<p>The <strong>latest version of this database is available upon registration</strong> at <a href="https://covid-nma.com/datasharing/">https://covid-nma.com/datasharing/</a>.</p>
<p>In fact, we are willing to make our database freely available to people who request it but it is important for us to know who is downloading our data and for which scope. We will reference in <a href="https://covid-nma.com">our website</a> every work produced using our data. </p>
https://doi.org/10.5281/zenodo.4266529
oai:zenodo.org:4266529
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.4266528
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
SARS-CoV-2
COVID-19
RCT studies on preventive measures and treatments for COVID-19
info:eu-repo/semantics/other
oai:zenodo.org:3855124
2020-08-14T15:03:44Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-26
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3855124
oai:zenodo.org:3855124
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3968490
2020-08-14T15:03:45Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-31
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3968490
oai:zenodo.org:3968490
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3835785
2020-08-14T15:03:43Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-20
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3835785
oai:zenodo.org:3835785
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3878725
2020-08-19T12:02:24Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-05
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3878725
oai:zenodo.org:3878725
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3947787
2020-08-19T12:02:26Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-16
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-RCT studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3947787
oai:zenodo.org:3947787
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3959130
2020-08-19T12:02:27Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-23
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3959130
oai:zenodo.org:3959130
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3968554
2020-08-19T12:02:27Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-31
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3968554
oai:zenodo.org:3968554
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3931346
2020-08-19T12:02:25Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-06
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-RCT studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3931346
oai:zenodo.org:3931346
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3835736
2020-08-19T12:02:23Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-20
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3835736
oai:zenodo.org:3835736
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3984937
2020-08-19T12:02:28Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-14
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3984937
oai:zenodo.org:3984937
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:5683529
2022-04-22T13:00:32Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Lina Ghosn
2020-10-23
<p>IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b).</p>
<p>In this review we aim to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly. </p>
<p> </p>
https://doi.org/10.5281/zenodo.5683529
oai:zenodo.org:5683529
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5654851
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
IL1 blocking agents, Interleukin inhibitors, IL1, IL1 Receptors, IL-1 blockade, Interleukin-1 Receptor Blockade, anakinra, canakinumab,COVID 19, COVID, coronavirus
Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review
info:eu-repo/semantics/other
oai:zenodo.org:5698123
2022-04-22T13:00:33Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Lina Ghosn
2021-11-08
<p>IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b).</p>
<p>In this review we aim to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly. </p>
<p> </p>
https://doi.org/10.5281/zenodo.5698123
oai:zenodo.org:5698123
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5654851
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
IL1 blocking agents, Interleukin inhibitors, IL1, IL1 Receptors, IL-1 blockade, Interleukin-1 Receptor Blockade, anakinra, canakinumab,COVID 19, COVID, coronavirus
Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review
info:eu-repo/semantics/other
oai:zenodo.org:5698219
2022-04-22T13:00:34Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Lina Ghosn
2020-10-23
<p>IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b).</p>
<p>In this review we aim to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly. </p>
<p> </p>
https://doi.org/10.5281/zenodo.5698219
oai:zenodo.org:5698219
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5654851
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
IL1 blocking agents, Interleukin inhibitors, IL1, IL1 Receptors, IL-1 blockade, Interleukin-1 Receptor Blockade, anakinra, canakinumab,COVID 19, COVID, coronavirus
Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review
info:eu-repo/semantics/other
oai:zenodo.org:5654852
2022-04-22T13:00:32Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Lina Ghosn
2021-11-08
<p>IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b).</p>
<p>In this review we aim to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly. </p>
<p> </p>
https://doi.org/10.5281/zenodo.5654852
oai:zenodo.org:5654852
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5654851
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
IL1 blocking agents, Interleukin inhibitors, IL1, IL1 Receptors, IL-1 blockade, Interleukin-1 Receptor Blockade, anakinra, canakinumab,COVID 19, COVID, coronavirus
Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review
info:eu-repo/semantics/other
oai:zenodo.org:5511936
2021-09-16T19:56:47Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
2021-09-16
<p>This is a protocol of a living systematic review of vaccine observational studies. Our aim is to assess the effectiveness of COVID-19 vaccines against SARS CoV-2 variants of concern Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) in addition to any other newly discovered variants of concerns as identified by WHO over time.. All results will be made available on the COVID-NMA platform (https://covid-nma.com/) and updated weekly.</p>
https://doi.org/10.5281/zenodo.5511936
oai:zenodo.org:5511936
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5511935
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
COVID-19 vaccines, COVID-19; Coronavirus; SARS-CoV2; Vaccine against SARS-CoV2;COVID-19 Vaccination;
Protocol effectiveness of COVID-19 vaccines on variant of concern. A systematic review of observational studies
info:eu-repo/semantics/article
oai:zenodo.org:5656885
2021-12-30T14:29:10Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Lina Ghosn
2021-11-09
<p>Interleukin (IL)-6 is a pleiotropic, pro-inflammatory cytokine produced by a variety of cell types, including lymphocytes, monocytes, and fibroblasts. IL-6 blocking agents are a class of therapeutics whose compounds are directed against either the IL-6 peptide or the IL-6 receptor. All currently available IL-6 blocking agents are monoclonal antibodies classified as anti-IL-6 receptor monoclonal antibodies (e.g., sarilumab, tocilizumab) and anti-IL-6 monoclonal antibodies (siltuximab). These include Tocilizumab, Sarilumab, Siltuximab, Levilimab, Olokizumab, and Clazakizumab. Other compounds might become available in the future.</p>
<p>In this review we aim to assess the effectiveness of IL-6 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19. </p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (<a>Boutron 2020</a>b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly. </p>
https://doi.org/10.5281/zenodo.5656885
oai:zenodo.org:5656885
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5656884
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
IL6 blocking agents, Interleukin inhibitors, IL6, IL6 Receptors, IL-6 blockade,monoclonal antibodies,sarilumab,Clazakizumab,Olokizumab,Levilimab,tocilizumab, siltuximab, Interleukin-6 Receptor Blockade, ,COVID 19, COVID, coronavirus
Interleukin (IL)-6 blocking agents for the treatment of COVID-19 A living systematic review
info:eu-repo/semantics/other
oai:zenodo.org:7118421
2022-09-28T14:26:23Z
user-covid-nma
openaire_data
user-covid-19
Phillip Kapp
Isabelle Boutron
2021-12-30
<p>We aimed to assess transparency of reporting and risk of bias of randomized trials evaluating interventions aimed at preventing and treating COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project (Boutron 2020a). The COVID-NMA project aims to provide decision-makers with a complete, high-quality and up-to-date synthesis of evidence on interventions for the prevention and treatment of COVID 19. For this purpose, we perform a living mapping of all registered randomized controlled trials and a living evidence synthesis of data from RCTs. We developed a master protocol on the effect of all interventions for the prevention and treatment of COVID-19 (first published on April 8, 2020; an update on May 11, 2020, June 17, 2020, and September 8, 2020) (Boutron 2020b). We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated weekly.</p>
https://doi.org/10.5281/zenodo.7118421
oai:zenodo.org:7118421
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5810075
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
COVID-19, reporting,CONSORT, transparency of reporting, randomized trials, RCT
Monitoring feedback to authors on the quality of trials evaluating interventions aimed at preventing and treating COVID-19
info:eu-repo/semantics/other
oai:zenodo.org:3964379
2020-08-13T15:23:04Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-28
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of protocols for RCTs on preventive measures and treatments for Covid-19.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3964379
oai:zenodo.org:3964379
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3931394
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Protocols for RCTs on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:7249070
2023-10-09T09:29:55Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Joerg J Meerpohl
Asbjørn Hróbjartsson
Declan Devane
Gabriel Rada
David Tovey
Giacomo Grasselli
Philippe Ravaud
2020-09-08
<p>WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.</p>
<p>To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).</p>
<p>This protocol details the process and methods we will use.</p>
https://doi.org/10.5281/zenodo.7249070
oai:zenodo.org:7249070
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3744599
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Interventions for preventing and treating COVID-19: living systematic reviews and network meta-analyses
info:eu-repo/semantics/report
oai:zenodo.org:4018607
2023-10-09T09:29:54Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Joerg J Meerpohl
Asbjørn Hróbjartsson
Declan Devane
Gabriel Rada
David Tovey
Giacomo Grasselli
Philippe Ravaud
2020-09-08
<p>WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.</p>
<p>To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).</p>
<p>This protocol details the process and methods we will use.</p>
https://doi.org/10.5281/zenodo.4018607
oai:zenodo.org:4018607
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3744599
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Interventions for preventing and treating COVID-19: living systematic reviews and network meta-analyses
info:eu-repo/semantics/report
oai:zenodo.org:3947790
2020-08-13T15:23:04Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-16
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of protocols for RCTs on preventive measures and treatments for Covid-19.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3947790
oai:zenodo.org:3947790
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3931394
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Protocols for RCTs on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3931428
2020-08-14T15:03:44Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-06
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3931428
oai:zenodo.org:3931428
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3985790
2020-08-15T00:59:23Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-14
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3985790
oai:zenodo.org:3985790
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3898629
2020-08-14T15:03:44Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-17
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3898629
oai:zenodo.org:3898629
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3898626
2020-06-17T22:18:22Z
user-covid-nma
openaire_data
user-covid-19
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-17
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of modelling studies on preventive measures and treatments for Covid-19.</p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3898626
oai:zenodo.org:3898626
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3823991
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Modelling studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3823992
2020-06-17T13:57:49Z
user-covid-nma
openaire_data
user-covid-19
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-13
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of modelling studies on preventive measures and treatments for Covid-19.</p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3823992
oai:zenodo.org:3823992
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3823991
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Modelling studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3909575
2020-08-13T15:11:25Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-26
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3909575
oai:zenodo.org:3909575
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:5853927
2022-01-17T20:52:22Z
user-covid-nma
openaire_data
user-covid-19
Davidson, Mauricia
Menon, Sonia
Chaimani, Anna
Evrenoglou, Theodoros
Ghosn, Lina
Graña, Carolina
Henschke, Nicholas
Cogo, Elise
Villanueva, Gemma
Ferrand, Gabriel
Riveros, Carolina
Bonnet, Hillary
Kapp, Philipp
Moran, Conor
Devane, Declan
Meerpohl, Joerg J
Rada, Gabriel
Grasselli, Giacomo
Hróbjartsson, Asbjørn
Tovey, David
Ravaud, Philippe
Boutron, Isabelle
2022-01-15
<p>This dataset is used in the analyses reported in the review entitled "Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review"</p>
<p>IL-1 blockers are beneficial in inflammation-associated pathologies, such as rheumatoid arthritis (Mertens 2009) and possibly also in the subgroup of patients with severe sepsis where the inflammasome pathway is involved (Shakoory 2016). Similar benefits were reported in children with secondary macrophage activation syndrome, including cases triggered by viral infections (Mehta 2020b).</p>
<p>In this review we aimed to assess the effectiveness of IL-1 blocking agents compared to placebo, standard of care or no treatment on outcomes in patients with COVID-19.</p>
<p>This review is part of a larger project: the COVID-NMA project. We set-up a platform (<a href="https://covid-nma.com/">https://covid-nma.com</a>) where all our results are made available and updated bi-weekly. </p>
https://doi.org/10.5281/zenodo.5853927
oai:zenodo.org:5853927
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.5853926
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
IL1
IL1 blocking agents
Interleukin inhibitors
IL1 Receptors
IL-1 blockade
Interleukin-1 Receptor Blockade
anakinra
canakinumab
COVID 19
COVID
coronavirus
Dataset: Interleukin (IL)-1 blocking agents for the treatment of COVID-19 A living systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3901025
2020-08-13T15:11:24Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-18
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3901025
oai:zenodo.org:3901025
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3929667
2020-08-13T15:11:25Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-03
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3929667
oai:zenodo.org:3929667
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3939048
2020-08-19T12:02:26Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-10
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-RCT studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3939048
oai:zenodo.org:3939048
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3909571
2020-08-19T12:02:25Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-26
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3909571
oai:zenodo.org:3909571
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3929671
2020-08-19T12:02:25Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-03
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-RCT studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3929671
oai:zenodo.org:3929671
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3991719
2020-08-19T12:59:24Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-19
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3991719
oai:zenodo.org:3991719
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3982750
2020-08-19T12:02:28Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-13
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3982750
oai:zenodo.org:3982750
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:7198128
2022-10-14T14:26:33Z
user-covid-nma
user-covid-19
Carolina Graña
Anna Chaimani
Isabelle Boutron
2021-04-22
<p> </p>
<p> </p>
<p><strong>OBJECTIVES</strong></p>
<p>To assess the comparative efficacy, immunogenicity and safety of COVID-19 vaccines on SARS CoV-2 of any type (wild-type or variant) as well as SARS CoV-2 variants of concern Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) in addition to any other newly discovered variants of concerns as identified by WHO.</p>
<p> </p>
<p>This is a protocol of a living systematic review and network meta-analysis of randomized controlled trials (RCTs) evaluating COVID-19 vaccines. The living systematic review is part of the larger COVID-NMA initiative, (27)which aims to provide decision-makers with a complete, high-quality and up-to-date living systematic review on interventions for preventing and treating COVID-19. (28) This protocol on SARS-COV2 vaccines is a sub-protocol within the COVID-NMA project.</p>
<p>The NMA, where feasible, aims to provide results for all possible comparisons (direct and indirect) across different vaccines.</p>
<p> </p>
<p>This is the protocol for a Cochrane living systematic review. All results will be made available on the COVID-NMA platform (<a href="https://covid-nma.com">https://covid-nma.com</a>) and updated weekly.</p>
<p> </p>
<p>As this is an emerging topic and knowledge about this infection is evolving rapidly, we will set up regular meetings with content experts to update the protocol (e.g., definition of the nodes of the network, effect modifiers) and specify other important aspects (e.g., margin of equivalence).</p>
<p> </p>
<p>The review is registered in Prospero CRD42021271897.</p>
https://doi.org/10.5281/zenodo.7198128
oai:zenodo.org:7198128
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.6458271
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
covid19; vaccines SARSCOV2; Vaccines; Sarscov2; COVID-19
A systematic review and network meta-analysis of vaccine for COVID-19
info:eu-repo/semantics/article
oai:zenodo.org:6458272
2022-10-14T10:31:23Z
user-covid-nma
user-covid-19
Carolina Graña
Anna Chaimani
Isabelle Boutron
2021-04-22
<p> </p>
<p> </p>
<p><strong>OBJECTIVES</strong></p>
<p>To assess the comparative efficacy, immunogenicity and safety of COVID-19 vaccines on SARS CoV-2 of any type (wild-type or variant) as well as SARS CoV-2 variants of concern Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) in addition to any other newly discovered variants of concerns as identified by WHO.</p>
<p> </p>
<p>This is a protocol of a living systematic review and network meta-analysis of randomized controlled trials (RCTs) evaluating COVID-19 vaccines. The living systematic review is part of the larger COVID-NMA initiative, (27)which aims to provide decision-makers with a complete, high-quality and up-to-date living systematic review on interventions for preventing and treating COVID-19. (28) This protocol on SARS-COV2 vaccines is a sub-protocol within the COVID-NMA project.</p>
<p>The NMA, where feasible, aims to provide results for all possible comparisons (direct and indirect) across different vaccines.</p>
<p> </p>
<p>This is the protocol for a Cochrane living systematic review. All results will be made available on the COVID-NMA platform (<a href="https://covid-nma.com">https://covid-nma.com</a>) and updated weekly.</p>
<p> </p>
<p>As this is an emerging topic and knowledge about this infection is evolving rapidly, we will set up regular meetings with content experts to update the protocol (e.g., definition of the nodes of the network, effect modifiers) and specify other important aspects (e.g., margin of equivalence).</p>
<p> </p>
<p>The review is registered in Prospero CRD42021271897.</p>
https://doi.org/10.5281/zenodo.6458272
oai:zenodo.org:6458272
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.6458271
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
covid19; vaccines SARSCOV2; Vaccines; Sarscov2; COVID-19
A systematic review and network meta-analysis of vaccine for COVID-19
info:eu-repo/semantics/article
oai:zenodo.org:6452030
2022-04-12T19:43:59Z
user-covid-nma
user-covid-19
The COVID-NMA team
2022-04-12
<p>Since the early months of the COVID-19 pandemic (March 2020), the COVID-NMA initiative, an international initiative working in conjunction with the World Health Organization (WHO), and led by a team of researchers from Cochrane and other institutions, has been producing relevant, accessible, up-to-date, and trustworthy synthesis of high-quality evidence about the efficacy and safety of interventions for the prevention or treatment of COVID-19, as well as mapping the trial evidence.</p>
<p>As part of a broader strategy to disseminate the results of the COVID-NMA initiative more effectively, we will be generating monthly reports summarizing our main findings. Our goal is to present an overview of what is known with moderate or high certainty, highlighting the interventions that appear to be effective or not, to make it easy for researchers and guideline developers to stay up to date with the current evidence on the prevention and treatment of COVID-19.</p>
<p>The information in this first edition of the Summary of Main Results report represents the COVID-NMA results up to April 4th, 2022. Given the living nature of this review, though, the most up to date results will be available on covid-nma.com, and any studies pending data extraction are available covid-nma.com.</p>
https://doi.org/10.5281/zenodo.6452030
oai:zenodo.org:6452030
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.6452029
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
covid-19; covid; living systematic review, treatments for covid; coronvirus, SARS-CoV 2
Current evidence regarding treatment of hospitalized Covid-19 patients. Summary of main results: April 2022
info:eu-repo/semantics/report
oai:zenodo.org:4605399
2021-12-30T14:27:27Z
user-covid-nma
Lina Ghosn
Anna Chaimani
Theodoros Evrenoglou
Mauricia Davidson
Carolina Graña
Christine Schmucker
Claudia Bollig
Nicholas Henschke
Yanina Sguassero
Camila Hansen Nejstgaard
Sonia Menon
Thu Van Nguyen
Gabriel Ferrand
Philipp Kapp
Carolina Riveros
Camila Ávila
Declan Devane
Joerg J Meerpohl
Gabriel Rada
Asbjørn Hróbjartsson
Giacomo Grasselli
David Tovey
Philippe Ravaud
Isabelle Boutron
2021-03-15
<p>Table of outcomes effect size and relevant forest plots per outcome for IL-6 blocking agents (Tocilizumab/sarilumab) as compared to standard of care/placebo; including primary analysis, sensitivity and subgroup analysis.</p>
https://doi.org/10.5281/zenodo.4605399
oai:zenodo.org:4605399
eng
Zenodo
https://doi.org/10.1002/14651858.CD013881
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.4605398
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Table of outcomes effect size and forest plots per outcome
info:eu-repo/semantics/other
oai:zenodo.org:3975663
2020-08-13T15:23:05Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-07
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of protocols for RCTs on preventive measures and treatments for Covid-19.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3975663
oai:zenodo.org:3975663
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3931394
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Protocols for RCTs on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3931395
2020-08-13T15:23:03Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-06
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of protocols for RCTs on preventive measures and treatments for Covid-19.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3931395
oai:zenodo.org:3931395
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3931394
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Protocols for RCTs on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3855131
2020-08-07T14:27:32Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-26
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3855131
oai:zenodo.org:3855131
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3898632
2020-08-07T14:27:33Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-17
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3898632
oai:zenodo.org:3898632
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3959134
2020-08-07T14:27:33Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-23
<p>In the course of our MedRxiv searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3959134
oai:zenodo.org:3959134
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835798
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in MedRxiv and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3959132
2020-08-13T15:11:26Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-23
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3959132
oai:zenodo.org:3959132
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3947791
2020-08-13T15:11:26Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-16
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3947791
oai:zenodo.org:3947791
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3833810
2020-08-13T15:11:23Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-19
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3833810
oai:zenodo.org:3833810
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3931383
2020-08-13T15:11:25Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-06
<p>In the course of our PubMed searches and preprints from MedRxiv, we identified a number of observational studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3931383
oai:zenodo.org:3931383
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3833809
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Observational studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3855135
2020-06-17T13:57:49Z
user-covid-nma
openaire_data
user-covid-19
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-26
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of modelling studies on preventive measures and treatments for Covid-19.</p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3855135
oai:zenodo.org:3855135
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3823991
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Modelling studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3975888
2020-08-14T15:03:45Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-07
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3975888
oai:zenodo.org:3975888
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3959989
2020-08-14T15:03:45Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-23
<p>In the course of our PubMed searches we identified and screened the title and abstract of a number of studies on Covid-19 that were finally excluded from our systematic review. </p>
<p>This file will be updated regularly.</p>
https://doi.org/10.5281/zenodo.3959989
oai:zenodo.org:3959989
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835784
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
List of studies on Covid-19 identified in PubMed and excluded from our systematic review
info:eu-repo/semantics/other
oai:zenodo.org:3903347
2023-10-09T09:29:54Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Joerg J Meerpohl
Asbjørn Hróbjartsson
Declan Devane
Gabriel Rada
David Tovey
Giacomo Grasselli
Philippe Ravaud
2020-06-17
<p>WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.</p>
<p>To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).</p>
<p>This protocol details the process and methods we will use.</p>
https://doi.org/10.5281/zenodo.3903347
oai:zenodo.org:3903347
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3744599
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review
info:eu-repo/semantics/report
oai:zenodo.org:3744600
2023-10-09T09:29:54Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-04-08
<p>WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.</p>
<p>To this end, we will perform a living mapping of ongoing randomized trials, followed by living systematic reviews with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).</p>
<p>This protocol details the process and methods we will use.</p>
https://doi.org/10.5281/zenodo.3744600
oai:zenodo.org:3744600
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3744599
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Interventions for preventing and treating COVID-19: protocol for a living mapping of research and a living systematic review
info:eu-repo/semantics/report
oai:zenodo.org:8420533
2023-10-09T09:29:56Z
user-covid-nma
user-covid-19
Isabelle Boutron
Anna Chaimani
Joerg J Meerpohl
Asbjørn Hróbjartsson
Declan Devane
Gabriel Rada
David Tovey
Giacomo Grasselli
Philippe Ravaud
2023-09-01
<p>WHO declared COVID-19 a pandemic on March 11, 2020. Researchers are working to accelerate the development of diagnostic tests, preventive interventions and therapeutic interventions. Many randomized trials have been established to evaluate candidate therapeutic agents that may effectively reduce symptoms and avoid deaths. This emerging situation requires the optimal planning and conduct of trials as well as strategies for the appropriate translation of research into practice. Therefore, decision-makers and researchers urgently need a complete, high-quality and up-to-date synthesis of data from all ongoing research studies as soon as they are available.</p>
<p>To this end, we will perform a living mapping of registered randomized trials and a living systematic review with pairwise meta-analyses and when possible, network meta-analyses focusing on two main questions: 1) the effectiveness of preventive interventions for COVID-19 and 2) the effectiveness of treatment interventions for COVID-19. We will evaluate the impact of these treatments considering the severity of the disease (i.e., mild, moderate, severe and critical diseases).</p>
<p>This protocol details the process and methods we will use.</p>
https://doi.org/10.5281/zenodo.8420533
oai:zenodo.org:8420533
eng
Zenodo
https://zenodo.org/communities/covid-19
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3744599
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
Interventions for preventing and treating COVID-19: living systematic reviews and network meta-analyses
info:eu-repo/semantics/other
oai:zenodo.org:4369234
2021-01-15T12:36:26Z
user-covid-nma
openaire_data
Oikonomidi Theodora
Isabelle Boutron
Olivier Pierre
Guillaume Cabanac
Philippe Ravaud
The COVID-NMA Consortium
2020-12-20
<p>This dataset was used in the analyses reported in Oikonomidi, T., Boutron, I., Pierre, O. et al. Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Med 18, 402 (2020). https://doi.org/10.1186/s12916-020-01880-8. </p>
<p>This project is ancillary to the COVID-NMA Living systematic review and network meta-analysis of Covid-19 trials: https://covid-nma.com/</p>
<p>The first spreadsheet entitled "key" includes the full description of the dataset.</p>
https://doi.org/10.5281/zenodo.4369234
oai:zenodo.org:4369234
eng
Zenodo
https://doi.org/10.1186/s12916-020-01880-8
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.4369233
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
BMC Medicine, 18, (2020-12-20)
Dataset for article: Changes in evidence for studies assessing interventions for COVID-19 reported in preprints: meta-research study. BMC Med 18, 402 (2020).
info:eu-repo/semantics/other
oai:zenodo.org:3901030
2020-08-19T12:02:24Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-06-18
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3901030
oai:zenodo.org:3901030
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3855497
2020-08-19T12:02:24Z
user-covid-nma
openaire_data
Carolina Riveros
Chantal Julia
Astrid Chevance
Fiona Quirke
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-05-26
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file will be updated regularly (once a week).</p>
https://doi.org/10.5281/zenodo.3855497
oai:zenodo.org:3855497
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and quasi-experimental studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3974233
2020-08-19T12:02:28Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-06
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3974233
oai:zenodo.org:3974233
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3966916
2020-08-19T12:02:27Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-30
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3966916
oai:zenodo.org:3966916
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3949746
2020-08-19T12:02:26Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-07-20
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-RCT studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3949746
oai:zenodo.org:3949746
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3972107
2020-08-19T12:02:27Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-04
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3972107
oai:zenodo.org:3972107
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other
oai:zenodo.org:3988415
2020-08-19T12:02:29Z
user-covid-nma
openaire_data
Carolina Riveros
Olivier Pierre
Leopold Fezeu
Fiona Quirke
Elizabeth Pienaar
Isabelle Boutron
Anna Chaimani
Declan Devane
Joerg J Meerpohl
David Tovey
Asbjørn Hróbjartsson
Philippe Ravaud
2020-08-17
<p>In the course of our PubMed searches and prepreints from MedRxiv, we identified a number of RCTs and non-randomized studies on preventive measures and treatments for Covid-19 that we have included in our systematic review.</p>
<p>This file is updated regularly.</p>
https://doi.org/10.5281/zenodo.3988415
oai:zenodo.org:3988415
eng
Zenodo
https://zenodo.org/communities/covid-nma
https://doi.org/10.5281/zenodo.3835735
info:eu-repo/semantics/openAccess
Creative Commons Attribution 4.0 International
https://creativecommons.org/licenses/by/4.0/legalcode
Covid-19
2019-nCoV
SARS-CoV-2
RCT
RCTs and non-RCT studies on preventive measures and treatments for Covid-19
info:eu-repo/semantics/other